[Cancer therapy by using bispecific antibody]

Area of Science:

• Immunology
• Biotechnology
• Oncology

Context:

• Bispecific antibodies (BsAbs) are engineered proteins with two distinct antigen-binding sites.
• Recent advancements have expanded their potential in various clinical applications, particularly in immunotherapy.
• Challenges in production and purification have historically limited their widespread use.

Purpose:

• To review current research and clinical trials involving bispecific antibodies.
• To discuss the theoretical underpinnings and manufacturing challenges of BsAbs.
• To propose a novel manufacturing strategy for enhanced clinical utility.

Summary:

• This review covers recent research and clinical trials on bispecific antibodies for immunotherapy.
• It explores their potential in targeting tumor cells, effector cells, and delivering therapeutic payloads.
• The paper discusses production, purification, and conjugation techniques, highlighting limitations.
• A new genetic engineering-based manufacturing strategy is proposed to overcome these challenges.

Impact:

• The proposed genetic engineering approach aims to facilitate the broad clinical application of bispecific antibodies.
• This could significantly advance cancer immunotherapy by improving targeting and efficacy.
• Enhanced production methods may lead to more accessible and effective cancer treatments.